Aberrant huntingtin interacting protein 1 in lymphoid malignancies

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8923-8931

  Bradley, Sarah V ^a   Smith, Mitchell R ^b   Hyun, Teresa S ^a   Lucas, Peter C ^a   Li, Lina ^a   Antonuk, Danielle ^a   Joshi, Indira ^b   Jin, Fang ^b   Ross, Theodora S ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ANTIBODY; BIOLOGICAL MARKER; CLATHRIN; COLONY STIMULATING FACTOR 1; CYCLIN D1; HUNTINGTIN; HUNTINGTIN INTERACTING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B CELL LYMPHOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENOTYPE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TATA BOX; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, NEOPLASM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548730846     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2153     Document Type: Article

References (39)

1. Wanker EE, Rovira C, Scherzinger E, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997;6:487-95.
2. Kalchman MA, Koide HB, McCutcheon K, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 1997;16:44-53.
3. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998; 91:4419-26.
4. Rao DS, Hyun TS, Kumar PD, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002;110:351-60.
5. Rao DS, Bradley SV, Kumar PD, et al. Altered receptor trafficking in huntingtin interacting protein 1-transformed cells. Cancer Cell 2003;3:471-82.
6. Bradley SV, Oravecz-Wilson KI, Bougeard G, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005;65: 4126-33.
7. Hyun TS, Rao DS, Saint-Dic D, et al. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J Biol Chem 2004;279:14294-306.
8. Metzler M, Legendre-Guillemin V, Gan L, et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem 2001;276:39271-6.
9. Mishra SK, Agostinelli NR, Brett TJ, Mizukami I, Ross TS, Traub LM. Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins. J Biol Chem 2001;276:46230-6.
10. Rao DS, Chang JC, Kumar PD, et al. Huntingtin interacting protein 1 is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors. Mol Cell Biol 2001;21:7796-806.
11. Waelter S, Scherzinger E, Hasenbank R, et al. The huntingtin interacting protein HIP1 is a clathrin and α-adaptin-binding protein involved in receptor-mediated endocytosis. Hum Mol Genet 2001;10:1807-17.
12. Rees DJ, Ades SE, Singer SJ, Hynes RO. Sequence and domain structure of talin. Nature 1990;347:685-9.
13. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. HIP1 is a novel brain tumor marker that associates with the EGFR. Cancer Res 2007;67:3609-15.
14. Lu P. Staging and classification of lymphoma. Semin Nucl Med 2005;35:160-4.
15. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-505.
16. Kuppers R, Schwering I, Brauninger A, Rajewsky K, Hansmann ML. Biology of Hodgkin's lymphoma. Ann Oncol 2002;13 Suppl 1:11-8.
17. Smith MR, Joshi I, Jin F, Al-Saleem T. Murine model for mantle cell lymphoma. Leukemia 2006;20:891-3.
18. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
19. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 1991; 88:9638-42.
20. Dube N, Bourdeau A, Heinonen KM, Cheng A, Loy AL, Tremblay ML. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res 2005;65:10088-95.
21. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004;114:206-13.
22. Collin-Osdoby P, Yu X, Zheng H, Osdoby P. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Med 2003;80:153-66.
23. Oravecz-Wilson KI, Kiel MJ, Li L, et al. Huntingtin interacting protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts. Hum Mol Genet 2004;13:851-67.
24. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991;11:4846-53.
25. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5.
26. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994;13:2124-30.
27. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356: 215-21.
28. Bradley SV, Hyun TS, Oravecz-Wilson KI, et al. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1. Hum Mol Genet 2007;16:1279-92.
29. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 2007;109:2700-7.
30. Horie R, Watanabe T, Morishita Y, et al. Ligandindependent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002;21:2493-503.
31. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53.
32. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-5.
33. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 2001;98:2784-90.
34. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
35. Jezersek B, Rudolf Z, Novakovic S. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. Oncol Rep 2001;8:77-81.
36. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leuk Lymphoma 1992;7:117-22.
37. Swissa M, Amital-Teplizki H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer 1990;65:2554-8.
38. Kuan AP, Cohen PL. p53 is required for spontaneous autoantibody production in B6/lpr lupus mice. Eur J Immunol 2005;35:1653-60.
39. Chigira S, Sugita K, Kita K, et al. Increased expression of the huntingtin interacting protein-1 gene in cells from Hutchinson Gilford syndrome (progeria) patients and aged donors. J Gerontol A Biol Sci Med Sci 2003;58: 873-8.